Abbott Laboratories (NYSE:ABT) Stock Gets Price Target Reduction from TD Cowen

Abbott Laboratories (NYSE:ABT) had its target price reduced by TD Cowen from $135.00 to $118.00 in a research note issued to investors on Thursday morning,Benzinga reports. TD Cowen currently has a buy rating on the healthcare product maker’s stock.

Several other analysts have also recently weighed in on ABT. UBS Group dropped their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Rothschild & Co Redburn raised Abbott Laboratories from a “neutral” rating to a “buy” rating and raised their price target for the company from $119.00 to $127.00 in a report on Friday, October 2nd. Finally, Barclays assumed coverage on shares of Abbott Laboratories in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $118.32.

Abbott Laboratories Trading Up 1.2%

Shares of ABT stock opened at $103.70 on Thursday. The stock’s 50-day moving average price is $105.15 and its 200-day moving average price is $98.32. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $179.45 billion, a price-to-earnings ratio of 38.70, a price-to-earnings-growth ratio of 1.92 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts’ consensus estimates of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.30 earnings per share. Equities research analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 94.03%.

Institutional Trading of Abbott Laboratories

Hedge funds and other institutional investors have recently bought and sold shares of the business. Manning & Napier Advisors LLC bought a new stake in Abbott Laboratories in the second quarter valued at approximately $31,000. Summit Securities Group LLC grew its position in shares of Abbott Laboratories by 41.3% in the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock valued at $37,000 after purchasing an additional 118 shares during the last quarter. Addison Advisors LLC acquired a new position in shares of Abbott Laboratories in the 2nd quarter worth approximately $40,000. Hoey Investments Inc. raised its stake in shares of Abbott Laboratories by 59.3% during the 1st quarter. Hoey Investments Inc. now owns 446 shares of the healthcare product maker’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. boosted its holdings in Abbott Laboratories by 221.6% in the second quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker’s stock valued at $43,000 after acquiring an additional 328 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.